IGM Biosciences has updated its merger terms, offering shareholders USD 1.2470 in cash and an additional share for each IGMS share held. This cash and stock structure aims to clarify valuation for existing shareholders. The company continues its focus on developing innovative therapies while navigating the complexities of the merger.
Company Information
Company
IGM Biosciences
Location
325 E MIDDLEFIELD ROAD
Mountain View, California, United States
About
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers.
Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.
Don't miss IGM Biosciences's next move
Get an email the moment IGM Biosciences makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired IGM Biosciences?
IGM Biosciences was acquired by IGM Biosciences, based in Mountain View. The deal was reported on September 17, 2026. IGM Biosciences is privately held and operates in Biotechnology.
When did IGM Biosciences acquire IGM Biosciences?
IGM Biosciences's acquisition of IGM Biosciences was reported on September 17, 2026. IGM Biosciences has updated its merger terms, offering shareholders USD 1.2470 in cash and an additional share for each IGMS share held. This cash and stock structure aims to clarify valuation for existing shareholders. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does IGM Biosciences do?
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. It is privately held, operating in Biotechnology, and is based in Mountain View.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
Mountain View